Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2017 Jun;31(3):229-232.
doi: 10.1007/s10557-017-6741-2.

Mechanistic Insights of Empagliflozin-Mediated Cardiac Benefits: Nearing the Starting Line : Editorial to: "Empagliflozin Improves Left Ventricular Diastolic Dysfunction in a Genetic Model of Type 2 Diabetes" by N. Hammoudi et al

Manisha Gupte  1 , Prachi Umbarkar  1 , Hind Lal  2
Affiliations
Editorial

Mechanistic Insights of Empagliflozin-Mediated Cardiac Benefits: Nearing the Starting Line : Editorial to: "Empagliflozin Improves Left Ventricular Diastolic Dysfunction in a Genetic Model of Type 2 Diabetes" by N. Hammoudi et al

Manisha Gupte et al. Cardiovasc Drugs Ther. 2017 Jun.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: All authors declared no conflict of interest.

Figures

Figure
Figure. Potential signaling mechanism for the beneficial effect of Empagliflozin (EMPA) on cardiac function
Multiple pathways have been implicated in the myocardial pathophysiology. Many of these diverse signaling cascades culminate into MAP kinases and AKT as the final effector molecule to modulate the gene program of cardiac remodeling and heart failure. The final effectors that are modulated by EMPA are shown. AKT, AKT8 virus oncogene cellular homolog; ECM, extracellular matrix; ERK, extracellular signal-regulated kinase; FAK, focal adhesion kinase; GPCR, G-protein coupled receptor; Grb2, growth factor receptor-bound protein 2; GRK2, G-protein coupled receptor kinase; ILK, integrin-linked kinase; IRS, insulin receptor substrate; JNK = Jun N-terminal kinase; MEK, MAPK/Erk kinase; PDK1, 3-phosphoinositide-dependent protein kinase 1; PI3K, phosphoinositide 3 kinase; PKA, protein kinase A; PLB, phospholamban; Rac1, Ras-related C3 botulinum toxin substrate 1; Raf, Rapidly Accelerated Fibrosarcoma; RhoA, Ras homolog gene family, member A; RTK, receptor tyrosine kinase; SERCA2a, sarcoplasmic/endoplasmic reticulum Ca2+-ATPase; SOS, Son of sevenless guanine nucleotide exchange factor; TAK1, TGF β-activated kinase 1; TGFR, TGF-β1 receptor.
See this image and copyright information in PMC

Comment on

References

    1. Abdul-Ghani MA, Norton L, DeFronzo RA. Renal sodium-glucose cotransporter inhibition in the management of type 2 diabetes mellitus. Am J Physiol Renal Physiol. 2015;309(11):F889–900. - PMC - PubMed
    1. Raz I, Cahn A. Heart failure: SGLT2 inhibitors and heart failure – clinical implications. Nat Rev Cardiol. 2016;13(4):185–6. - PubMed
    1. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373(22):2117–28. - PubMed
    1. Fitchett D, Zinman B, Wanner C, Lachin JM, Hantel S, Salsali A, et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME(R) trial. Eur Heart J. 2016;37(19):1526–34. - PMC - PubMed
    1. Kaku K, Lee J, Mattheus M, Kaspers S, George J, Woerle HJ, et al. Empagliflozin and Cardiovascular Outcomes in Asian Patients With Type 2 Diabetes and Established Cardiovascular Disease – Results from EMPA-REG OUTCOME. Circ J. 2017;81:227–234. - PubMed

LinkOut - more resources